FDA News

Moderna Will Have to Wait for FDA Approval of Investigational RSV Vaccine
May 10, 2024

While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.

Donanemab FDA AdComm Hearing Scheduled for June 10, Eli Lilly Says
May 08, 2024

The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.

FDA Approves ColoSense, Novel Noninvasive Multitarget Stool RNA CRC Screening Test
May 07, 2024

In average-risk individuals, the at-home ColoSense test demonstrated 93% sensitivity for detecting CRC and 45% sensitivity for detecting advanced adenomas.

sNDA for Brexpiprazole/Sertraline Combination for PTSD Submitted for FDA Review
May 03, 2024

The sNDA for the brexpiprazole plus sertraline therapy is based on positive phase 2 and 3 clinical trials showing improvement in PTSD-specific scale scores.

FDA Approves New Antibiotic for Uncomplicated UTI: Daily Dose
May 03, 2024

Your daily dose of the clinical news you may have missed.

The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
April 30, 2024

Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.

The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
April 26, 2024

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

FDA Approves First New Antibiotic in Decades for Uncomplicated UTI
April 25, 2024

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.

Vedolizumab (Entyvio) SC Approved for Maintenance Therapy in Adults with Moderately to Severely Active Crohn Disease
April 22, 2024

Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children with Severe Asthma: Daily Dose
April 19, 2024

Your daily dose of the clinical news you may have missed.